Development of pyridazine derivatives as potential EGFR inhibitors and apoptosis inducers: Design, synthesis, anticancer evaluation, and molecular modeling studies
作者:Marwa F. Ahmed、Eman Y. Santali、Eman M. Mohi El-Deen、Ibrahim A. Naguib、Radwan El-Haggar
DOI:10.1016/j.bioorg.2020.104473
日期:2021.1
On the other hand, molecular docking study was performed to investigate binding mode of interaction of compounds with EGFR-PK in the active site with the aim of rationalizing its promising inhibitory activity. Finally, based on the aforementioned findings, compounds IXg and IXn could be considered as effective apoptosis modulators and promising leads for future development of new anti-renal cancer agents
合成了哒嗪-吡唑啉的新型杂化物,旨在开发新的抗增殖候选物。所有化合物都提交给美国国家癌症研究所 (NCI),其中许多化合物被证明具有显着的抗增殖活性。此外,在体外的表皮生长因子受体的研究(EGFR)抑制表明化合物IXn,IXG,IXb的和IXL显示出优异的抑制效果(IC 50相比,埃罗替尼(IC = 0.65,0.75,0.82和0.84μM,分别地)50 = 0.95 μM)。评估了有希望的化合物IXg在细胞周期进程、凋亡诱导和基因调控方面的机制有效性和IXn由于它们显着的 EGFR 抑制作用。流式细胞术分析表明,化合物IXg和IXn导致 G2/M 期细胞数量增加,表明 UO-31 细胞中 G2/M 期的细胞周期停滞。此外,实时 PCR 测定表明化合物IXg和IXn提高了 Bax/Bcl2 比率,这证实了它们的机制途径。此外,化合物IXg和IXn通过激活caspase-3有效增强了UO-31肾癌细胞的凋亡诱导